Ion Beam Applications SA (0GZK.L)

16,98 +0,38 (+2,29%) Börsenschluss: 05:50PM BST

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve 1348
Belgium
32 1 047 58 11
https://www.iba-worldwide.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 1.986

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Pierre Mottet	Chairman of The Board	61,5k	N/A	1962
Mr. Olivier Legrain	CEO, MD & Executive Director	815,89k	N/A	1968
Mr. Yves Jongen	Founder, Chief Research Officer, MD & Executive Director	564,08k	N/A	1947
Ms. Soumya Chandramouli	Chief Financial Officer	N/A	N/A	1977
Mr. Frederic Nolf	Chief Human Resources & Sustainability Officer	N/A	N/A	1972
Marc Van der Burght	Chief Operation Officer	N/A	N/A	N/A
Olivier Lechien	Corporate Communication Director	N/A	N/A	N/A
Thomas Canon	Sustainability Program Director	N/A	N/A	N/A
Bruno Scutnaire	President of IBA RadioPharma Solutions	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Corporate Governance

Ion Beam Applications SAs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 3, Vorstand: 9, Shareholderrechte: 9, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.